CD39/Adenosine Pathway and AIDS Progression
Author Information
Author(s): Nikolova Maria, Carriere Matthieu, Jenabian Mohammad-Ali, Limou Sophie, Younas Mehwish, Kök Ayrin, Huë Sophie, Seddiki Nabila, Hulin Anne, Delaneau Olivier, Schuitemaker Hanneke, Herbeck Joshua T., Mullins James I., Muhtarova Maria, Bensussan Armand, Zagury Jean-François, Lelievre Jean-Daniel, Lévy Yves
Primary Institution: INSERM, Unite U955, Creteil, France
Hypothesis
The CD39/adenosine pathway is involved in the pathogenesis of HIV-1 disease.
Conclusion
The study found that the expansion of Treg CD39+ cells correlates with immune activation and lower CD4+ counts in HIV-1 infected patients.
Supporting Evidence
- HIV-1 positive patients show a significant increase in Treg-associated expression of CD39.
- Treg CD39+ cells correlate with immune activation levels.
- CD39 down modulation relieves Treg suppression of CD8 T cells.
- A CD39 gene polymorphism is associated with slower progression to AIDS.
- Patients with ongoing viral replication show increased Treg CD39+ despite ART.
Takeaway
In people with HIV, a specific type of immune cell called Treg that has a marker called CD39 can make it harder for the body to fight the virus.
Methodology
The study involved analyzing Treg cells from HIV-positive patients and assessing their CD39 expression and function in vitro.
Limitations
The study was limited to peripheral blood and did not assess the role of the CD39/adenosine pathway in secondary lymphoid organs or mucosa.
Participant Demographics
Participants included HIV-positive individuals receiving antiretroviral therapy and those not receiving treatment.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website